One Stop Solution For In-Depth Market Research Reports


Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Gastroesophageal Reflux Disease Market

[ 英語タイトル ] Gastroesophageal Reflux Disease Market - Growth, Trends, and Forecast (2020 - 2025)

Product Code : MDHC0084135
Survey : Mordor Intelligence
Publish On : November, 2020
Category : Healthcare and Pharmaceuticals
Study Area : Global
Report format : PDF
Sales price option (consumption tax not included)
Single User USD4250 / Question Form
5 User USD4750 / Question Form
Enterprise User USD7500 / Question Form
- GlaxoSmithKline PLC
- SRS Life Sciences
- Johnson & Johnson Services, Inc.
- Medtronic Plc
- Olympus Corporation
- Pfizer, Inc.
- Reckitt Benckiser Group PLC
- Takeda Pharmaceutical Co., Ltd.
- Teva Pharmaceuticals Industries Limited.

[Report Description]

Market Overview

The major factors for the growth of the gastroesophageal reflux disease market include the rising prevalence of gastroesophageal reflux diseases and changing lifestyle, and increasing awareness about GERD.
According to the World Health Organization, in 2017, globally, more than USD 10 billion was spent every year on antacids. As per the World Gastroenterology Organization, the prevalence rate of GERD is growing rapidly across the world. It was valued at approximately 2.5%-6.6% in South East Asia and almost 13.8%-25.8% in North America. In the geriatric population, acidic complications are recurrent, which provides a unique challenge, for both, the primary care providers and gastroenterologists. Thus, rising cases of GERD the market is expected to witness high demand.

Scope of the Report

As per the scope of this report, Gastroesophageal Reflux Disease (GERD) covers various diagnostic and treatment of GERD. The GERD include discomfort or a burning sensation in the upper portion of the stomach, nausea, abdominal bloating, and belching. The most prescribed therapy for patients suffering from GERD is antacid therapy, mainly proton pump inhibitors (PPI).

Key Market Trends

Proton Pump Inhibitors is the Segment by Drug Type expected to Hold Largest Market Share over the Forecast Period

The Proton Pump Inhibitors (PPI) characterize the maximum potency in inhibiting gastric acid secretion, primarily by blocking the acid pump. These inhibitors are well-known, for both, therapeutic effects and good safety profiles. Heartburn and regurgitation are the most common acid reflux-related symptoms in Canadian patients, and many individuals self-diagnose and self-treat these symptoms. PPIs are the most successful short-term treatment for recurrent or severe heartburns. The OTC status of some PPI drugs is expected to augment their sales. There is an abundance of PPIs drugs, in both, branded and generic segments. Thus, owing to the all above-mentioned factors the market is expected to witness high growth.

North America is Expected to Hold Largest Market Share over the Forecast Period

The United States is expected to be the largest market owing to the presence of better healthcare infrastructure and the rising prevalence of GERD. In the United States, tablet (chewable form) and liquid forms are most widely used. There is a rising prevalence of GERD across the world, although there are marked differences in the reported prevalence, ranging from 14% to 26% in North America. However, it can be correlated with the rising prevalence of obesity, along with other dietary factors, in many countries. GERD can be associated with the impact on the quality of life and reduction in personal and work-related productivity. In the United States, major selling drugs include omeprazole, Pantoprazole Sodium, and Nexium. Thus, owing to the lifestyle change and rising cases of GERD the market is expected to grow.

Competitive Landscape

The market studied is a fragmented market owing to the presence of various market players. Some of the market players are GlaxoSmithKline PLC, Ironwood Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., Medtronic Plc, Olympus Corporation, Pfizer, Inc., Reckitt Benckiser Group PLC, Takeda Pharmaceutical Co., Ltd., and Teva Pharmaceuticals Industries Limited.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- Report customization as per the client's requirements
- 3 months of analyst support

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Gastrointestinal Reflux Diseases and Changing Lifestyle
4.2.2 Increasing Awareness about GERD
4.3 Market Restraints
4.3.1 Patent Expiry of Blockbuster Drugs
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Product
5.1.1 Diagnosis Upper Endoscopy Ambulatory Acid (pH) Probe Test Esophageal Manometry Others
5.1.2 Drug Type H-2-receptor Blockers Proton Pump Inhibitors Others
5.2 Geography
5.2.1 North America US Canada Mexico
5.2.2 Europe Germany UK France Italy Spain Rest of Europe
5.2.3 Asia Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.2.4 Middle East and Africa GCC South Africa Rest of Middle East and Africa
5.2.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 GlaxoSmithKline PLC
6.1.2 SRS Life Sciences
6.1.3 Johnson & Johnson Services, Inc.
6.1.4 Medtronic Plc
6.1.5 Olympus Corporation
6.1.6 Pfizer, Inc.
6.1.7 Reckitt Benckiser Group PLC
6.1.8 Takeda Pharmaceutical Co., Ltd.
6.1.9 Teva Pharmaceuticals Industries Limited.




Recommended reports